KOE · 468530.KQ
Proteina Co., Ltd.
₩54,200+₩300 (+0.56%)
Proteina Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.87% below the high.
Loading market information…
KOE · 064550.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 05:25 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Bioneer Corporation’s quoted price sits in the lower half of its reported 52-week range, 61.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Bioneer Corporation’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bioneer Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bioneer Corporation, established in 1992 and headquartered in Daejeon, South Korea, is a biotechnology company involved in diverse fields such as research products, molecular diagnostics, pharmaceuticals, and probiotics. For the biotechnology research market, Bioneer offers a wide array of consumables and reagents, including PCR and RT-PCR kits, real-time PCR solutions, RNA interference products, various chemicals, plastic laboratory essentials, and buffer solutions. The company also provides an extensive range of services like sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher services, electrophoresis, genome-wide functional analysis, and magnetic separation techniques. Additionally, Bioneer manufactures sophisticated instruments for conventional and real-time PCR, sample preparation, protein synthesis, centrifugation, vortex mixing, electrophoresis, spectrophotometry, and microbial culture. In molecular diagnostics, it supplies MDx technologies, human diagnostic kits, MDx extraction kits, and the necessary instrumentation. Furthermore, Bioneer develops specialized products for animal health and cutting-edge nano-biotechnology applications.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Feb 27, 2024 | -₩497 | ₩64.12B-17.8% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩54,200+₩300 (+0.56%)
Proteina Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 54.87% below the high.
₩8,150-₩200 (-2.4%)
MEDIPOST Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 71.99% below the high.
₩2,025-₩35 (-1.7%)
SillaJen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.59% below the high.
₩9,930+₩30 (+0.3%)
Genomictree Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.18% below the high.
₩2,505-₩55 (-2.15%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.78% below the high.
₩5,810-₩110 (-1.86%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.49% below the high.
₩3,680+₩60 (+1.66%)
Helixmith Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 63.05% below the high.
₩13,420-₩660 (-4.69%)
Anterogen.Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
